

# Iacopo Petrini

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6105445/iacopo-petrini-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73  
papers

1,945  
citations

23  
h-index

42  
g-index

91  
ext. papers

2,359  
ext. citations

5.7  
avg, IF

4.42  
L-index

#	Paper	IF	Citations
73	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 104, 102340	14.4	2
72	ED-B-Containing Isoform of Fibronectin in Tumor Microenvironment of Thymomas: A Target for a Theragnostic Approach. <i>Cancers</i> , <b>2022</b> , 14, 2592	6.6	2
71	Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: a retrospective review of 22 patients.. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 6373-6380	2.6	
70	Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 674604	5.3	1
69	Hyperthermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 957	3.2	1
68	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. <i>Pharmacological Research</i> , <b>2021</b> , 169, 105643	10.2	2
67	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1667-1678	7.4	8
66	Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients. <i>Molecular Cancer</i> , <b>2021</b> , 20, 32	42.1	7
65	Thymectomy in Myasthenic Patients With Thymoma: Killing Two Birds With One Stone. <i>Annals of Thoracic Surgery</i> , <b>2021</b> , 112, 1782-1789	2.7	4
64	Surgical treatment of pleural recurrence of thymoma: is hyperthermic intrathoracic chemotherapy worthwhile?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2020</b> , 30, 765-772	1.8	8
63	Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 593831	5.3	9
62	erbB in NSCLC as a molecular target: current evidences and future directions. <i>ESMO Open</i> , <b>2020</b> , 5,	6	12
61	Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 232-237	4.9	15
60	Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 573156	8.4	1
59	The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report. <i>BMC Cancer</i> , <b>2019</b> , 19, 410	4.8	11
58	From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. <i>Lung Cancer</i> , <b>2019</b> , 131, 78-85	5.9	28
57	Understanding the Mechanisms of Resistance in -Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	33

56	Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e14054-e14054	2.2	
55	Progression free survival and time to local failure after radiosurgery of pleural metastases in twenty-two patients with thymomas.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8565-8565	2.2	
54	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 820-824	8.7	117
53	The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. <i>Cell Death and Differentiation</i> , <b>2018</b> , 25, 1239-1258	12.7	47
52	EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. <i>Cancer Biomarkers</i> , <b>2018</b> , 21, 731-741	3.8	7
51	RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e811-e814	4.9	10
50	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. <i>Oncotarget</i> , <b>2018</b> , 9, 6630-6643	5.43	26
49	Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 210-210	2.2	
48	Medical treatment of malignant pleural mesothelioma relapses. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, S333-S341	2.6	4
47	The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1252-1258	8.7	26
46	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , <b>2018</b> , 71, 76-87	14.4	17
45	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 727-740	2.6	15
44	Human adult mesangiogenic progenitor cells reveal an early angiogenic potential, which is lost after mesengenic differentiation. <i>Stem Cell Research and Therapy</i> , <b>2017</b> , 8, 106	8.3	9
43	Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 692-697	4.9	36
42	ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology. <i>Oncotarget</i> , <b>2017</b> , 8, 4914-4921	3.3	25
41	Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup. <i>Oncotarget</i> , <b>2017</b> , 8, 79188-79200	3.3	5
40	Patients with NSCLC may display a low ratio of p.T790M activating EGFR mutations in plasma at disease progression: implications for personalised treatment. <i>Oncotarget</i> , <b>2017</b> , 8, 86056-86065	3.3	8
39	Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. <i>Oncotarget</i> , <b>2017</b> , 8, 13611-13619	3.3	66

38	Mutations Are Common in Thymic Epithelial Tumors But Not in Hematological Malignancies. <i>Anticancer Research</i> , <b>2017</b> , 37, 5459-5462	2.3	7
37	Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. <i>Oncology</i> , <b>2016</b> , 91, 311-316	3.6	8
36	Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 5697-5697	2.2	2
35	KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e20526-e20526	2.2	
34	Growth Factor Content in Human Sera Affects the Isolation of Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow. <i>Frontiers in Cell and Developmental Biology</i> , <b>2016</b> , 4, 114	5.7	4
33	Nanotopography Induced Human Bone Marrow (MPCs) to (MSCs) Transition. <i>Frontiers in Cell and Developmental Biology</i> , <b>2016</b> , 4, 144	5.7	2
32	The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of V600E Mutation in Hairy Cell Leukemia. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 363	5.6	17
31	Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications. <i>Epigenomics</i> , <b>2016</b> , 8, 1151-67	4.4	5
30	Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms. <i>International Journal of Laboratory Hematology</i> , <b>2015</b> , 37, 766-73	2.5	29
29	Biology of MET: a double life between normal tissue repair and tumor progression. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, 82	3.2	32
28	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2014</b> , 14, 453-68	3.8	16
27	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. <i>Nature Genetics</i> , <b>2014</b> , 46, 844-9	36.3	130
26	Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 414-8	8.9	23
25	Mutations of epigenetic regulatory genes are common in thymic carcinomas. <i>Scientific Reports</i> , <b>2014</b> , 4, 7336	4.9	85
24	Are MSCs angiogenic cells? New insights on human nestin-positive bone marrow-derived multipotent cells. <i>Frontiers in Cell and Developmental Biology</i> , <b>2014</b> , 2, 20	5.7	45
23	Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11056-11056	2.2	
22	Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in PhSNegative Myeloproliferative Neoplasms. <i>Blood</i> , <b>2014</b> , 124, 5548-5548	2.2	
21	Myelodysplastic Syndromes: A Multidisciplinary Integrated Diagnostic Work-up for PatientsSRisk Stratification. <i>Blood</i> , <b>2014</b> , 124, 5579-5579	2.2	

20	Reproducibility of the WHO classification of thymomas: practical implications. <i>Lung Cancer</i> , <b>2013</b> , 79, 236-41	5.9	30
19	Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1960-71	12.9	20
18	Whole genome and transcriptome sequencing of a B3 thymoma. <i>PLoS ONE</i> , <b>2013</b> , 8, e60572	3.7	21
17	CD57 and T-cell receptor expression in nodal metastatic spread of melanoma. <i>European Journal of Clinical Investigation</i> , <b>2012</b> , 42, 575-6	4.6	1
16	Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 69, 773-80	3.5	48
15	Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 524-33	12.9	19
14	Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. <i>Cell Death and Disease</i> , <b>2012</b> , 3, e351	9.8	42
13	Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. <i>Journal of Hematology and Oncology</i> , <b>2012</b> , 5, 53	22.4	7
12	NUT rearrangement is uncommon in human thymic epithelial tumors. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 744-50	8.9	15
11	Impaired function of gamma-delta lymphocytes in melanoma patients. <i>European Journal of Clinical Investigation</i> , <b>2011</b> , 41, 1186-94	4.6	15
10	Thymic malignancies: from clinical management to targeted therapies. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4820-7	2.2	100
9	MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. <i>Cancer Research</i> , <b>2010</b> , 70, 8288-98	10.1	108
8	Expression and mutational status of c-kit in thymic epithelial tumors. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 1447-53	8.9	48
7	Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. <i>Cancer</i> , <b>2010</b> , 116, 4686-95	6.4	43
6	A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 1720-4	8.7	27
5	Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells. <i>European Journal of Clinical Investigation</i> , <b>2009</b> , 39, 813-8	4.6	21
4	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2622-9	2.2	368
3	Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7, 7-14	3.8	15

2	Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4003-4003	2.2	13
1	Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. <i>Leukemia Research</i> , <b>2006</b> , 30, 529-35	2.7	13